Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rika Obata is active.

Publication


Featured researches published by Rika Obata.


Bioorganic & Medicinal Chemistry Letters | 1995

Chemical modification and structure-activity relationships of pyripyropenes; potent, bioavailable inhibitor of acyl-CoA: Cholesterol O-acyltransferase (ACAT)

Rika Obata; Toshiaki Sunazuka; Hiroshi Tomoda; Yoshihiro Harigaya; Satoshi Ōmura

Abstract Modification and structure-activity relationships of ACAT inhibitor pyripyropene were examined. PR-109 (7g) showed the most potent (IC50 = 6 nM) inhibitory activity. PR-86 (2e) also had strong inhibitory activity (IC50 = 19 nM) and its in vivo activity improved 10 times better (ED50 = 10 mg/kg) than that of pyripyropene A.


Bioorganic & Medicinal Chemistry Letters | 2000

Synthetic conversion of ACAT inhibitor to acetylcholinesterase inhibitor

Rika Obata; Toshiaki Sunazuka; Kazuhiko Otoguro; Hiroshi Tomoda; Yoshihiro Harigaya; Satoshi Ōmura

Natural product acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor pyripyropene A was synthetically converted to acetylcholinesterase (AChE) inhibitor via heterolitic cleavage of the 2-pyrone ring, followed by gamma-acylation/cyclization with several aroyl chlorides. The 4-pyridyl analogue selectively showed AChE inhibitory activity (IC50 7.9 microM) and no ACAT inhibitory activity IC50 = >1000 microM.


Journal of the American Chemical Society | 1994

RELATIVE AND ABSOLUTE STEREOCHEMISTRY OF PYRIPYROPENE A, A POTENT, BIOAVAILABLE INHIBITOR OF ACYL-COA : CHOLESTEROL ACYLTRANSFERASE (ACAT)

Hiroshi Tomoda; Hiroyuki Nishida; Young Kook Kim; Rika Obata; Toshiaki Sunazuka; Satoshi Omura; Jon Bordner; Mark A. Guadliana; Peter G. Dormer; Amos B. Smith


Journal of Organic Chemistry | 1995

Total Synthesis of (+)-Pyripyropene A, a Potent, Orally Bioavailable Inhibitor of Acyl-CoA:Cholesterol Acyltransferase

Tohru Nagamitsu; Toshiaki Sunazuka; Rika Obata; Hiroshi Tomoda; Haruo Tanaka; Yoshihiro Harigaya; Satoshi Omura; Amos B. Smith


The Journal of Antibiotics | 1996

Chemical modification and structure-activity relationships of pyripyropenes. 1. Modification at the four hydroxyl groups

Rika Obata; Toshiaki Sunazuka; Zhuorong Li; Zhiming Tian; Yoshihiro Harigaya; Noriko Tabata; Hiroshi Tomoda; Satoshi Omura


Journal of Organic Chemistry | 1996

BIOSYNTHESIS OF PYRIPYROPENE A

Hiroshi Tomoda; N. Tabata; Y. Nakata; Hiroyuki Nishida; Takushi Kaneko; Rika Obata; Toshiaki Sunazuka; Satoshi Omura


The Journal of Antibiotics | 2000

Structure-activity relationships study of pyripyropenes: Reversal of cancer cell multidrug resistance

Rika Obata; Toshiaki Sunazuka; Yoshihiro Harigaya; Masahiko Hayashi; Mun Chual Rho; Hiroshi Tomoda; Satoshi Omura


The Journal of Antibiotics | 1996

Chemical modification and structure-activity relationships of pyripyropenes. 2. 1,11-cyclic analogs

Rika Obata; Toshiaki Sunazuka; Yumiko Kato; Hiroshi Tomoda; Yoshihiro Harigaya; Satoshi Omura


The Journal of Antibiotics | 1997

Chemical Modification and Structure-activity Relationships of Pyripyropenes 3. Synthetic Conversion of Pyridine-pyrone Moiety

Rika Obata; Toshiaki Sunazuka; Zhiming Tian; Hiroshi Tomoda; Yoshihiro Harigaya; Satoshi Omura


The Journal of Antibiotics | 1995

Structure-activity relationships of pyripyropenes fungal acyl-CoA: cholesterol acyltransferase inhibitors.

Rika Obata; Toshiaki Sunazuka; Li Zhuorong; Hiroshi Tomoda; Satoshi Omura

Collaboration


Dive into the Rika Obata's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Amos B. Smith

University of Pennsylvania

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge